Treatment for Pancolitis

Introduction to Treatment

The American Gastroenterological Association recommends oral aminosalicylates as the first-line treatment for mild to moderate pancolitis, with mesalazine 2-4g daily or balsalazide 6.75g daily, often combined with topical therapy for symptomatic relief 1, 2

For patients with mild to moderate pancolitis, the European Crohn’s and Colitis Organisation suggests that oral aminosalicylates are the cornerstone of initial therapy: mesalazine 2-4g daily, balsalazide 6.75g daily, or olsalazine 1.5-3g daily 1, 2
The American College of Gastroenterology recommends that combination of oral and topical mesalazine is more effective than either alone for achieving remission 2
Once-daily dosing with mesalazine is as effective as divided doses, which may improve adherence, according to the National Institute for Health and Care Excellence 2
Topical therapy (mesalazine enemas 1g daily) can be added for troublesome rectal symptoms, as suggested by the American Gastroenterological Association 1, 2

If there is insufficient response to aminosalicylates, the European Crohn’s and Colitis Organisation recommends that oral prednisolone 40mg daily should be initiated 1, 2
Prednisolone should be tapered gradually over approximately 8 weeks according to patient response, as advised by the American College of Gastroenterology 1, 2
Topical agents may be used as adjunctive therapy with systemic corticosteroids, according to the British Society of Gastroenterology 3

Patients with severe disease require hospital admission for intensive intravenous therapy, as recommended by the American College of Gastroenterology 3, 2
Joint management by gastroenterologist and colorectal surgeon is essential, according to the European Crohn’s and Colitis Organisation 2
Monitoring should include daily physical examination for abdominal tenderness, vital signs four times daily, stool chart recording frequency and character of bowel movements, regular laboratory tests (CBC, CRP, electrolytes, albumin) every 24-48 hours, and abdominal radiography to assess for colonic dilatation, as suggested by the National Institute for Health and Care Excellence 3
Supportive care includes intravenous fluid and electrolyte replacement, blood transfusion to maintain hemoglobin >10 g/dl, subcutaneous heparin to reduce thromboembolism risk, and nutritional support if malnourished, according to the British Society of Gastroenterology 3

Lifelong maintenance therapy is generally recommended for all patients with pancolitis, as advised by the American Gastroenterological Association 3, 2
Aminosalicylates are effective and safe for maintenance therapy, according to the European Crohn’s and Colitis Organisation 2
For steroid-dependent disease, consider immunomodulators: Azathioprine 1.5-2.5 mg/kg/day or Mercaptopurine 0.75-1.5 mg/kg/day, as recommended by the American College of Gastroenterology 1, 2
Long-term steroid treatment should be avoided due to significant side effects, as suggested by the National Institute for Health and Care Excellence 1

Prefer immunomodulatory treatments with lower infection or malignancy risk in elderly patients, according to the American Gastroenterological Association 1
Avoid long-term steroid treatment in elderly patients, as advised by the European Crohn’s and Colitis Organisation 1
Consider the increased risk of adverse outcomes with severe disease in elderly patients, as suggested by the British Society of Gastroenterology 4
Employ a multidisciplinary approach to manage care and monitor for drug interactions in elderly patients, according to the American College of Gastroenterology 1

Proximal constipation should be treated with stool bulking agents or laxatives, as recommended by the National Institute for Health and Care Excellence 3, 2
Antidiarrheal medications can mask worsening symptoms while allowing underlying inflammation to progress, according to the American Gastroenterological Association 4
There is a theoretical risk that high-dose antidiarrheals may predispose to toxic dilatation, as suggested by the European Crohn’s and Colitis Organisation 4
Sulfasalazine (2-4g daily) has a higher incidence of side effects compared to newer aminosalicylates, according to the British Society of Gastroenterology 3, 2
Ensure appropriate vaccination schedules are followed before starting immunosuppression, as advised by the American College of Gastroenterology 1
Optimize comorbidities to minimize risks associated with treatment, according to the National Institute for Health and Care Excellence 1